BioWorld

June 15, 2004

View Archived Issues

Vertex's Deal With Mitsubishi: $33M To Boost HCV Research

Read More

Idun Placement Gets $27M To Progress Liver Therapy

Read More

Alexion, P&G Get FDA Clearance On Pexelizumab Phase III Design

Read More

Theravance Registers For $96M IPO To Advance Drug Programs

Read More

OSI Reports Anticipated Negative Results In Aptosyn Phase III Trial

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

QLT, Atrix Merging In $855M Deal To Grow Pipeline, Build Business

In a transaction valued at $855 million, QLT Inc. and Atrix Laboratories Inc. are merging into a single entity with two marketed products and a multitude of pipeline possibilities. (BioWorld Today) Read More